CRNX News and Press, Crinetics Pharmaceuticals Inc. From 08/12/22

Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q2 GAAP EPS of -$0.81 misses by $0.15 . Revenue of $0.44M misses by $0.28M . Based on its current plans, the company expects that current cash, cash equivalents and short-term investments will fund its c...

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenit...

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,100 ...

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral...

Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2; Results from both studies expected 2023. Paltusotine is also being explored for the treatment of patients with neuroendocrine tumors in a phase 2 study. Phase 1 proo...

SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894 , the company’s investigational candidate for the treatment of Cushing’s disease, congenital adren...

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced tha...

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported results from a multiple-ascending dose (MAD) portion of a phase 1 trial in healthy people of its oral adrenocorticotropic hormone (ACTH) CRN04894, being explored to treat Cushing’s disease, congenital adrenal hyperplasia (CAH). When the ...

Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuti...

Crinetics Pharmaceuticals press release (NASDAQ:CRNX): Q1 GAAP EPS of -$0.73 misses by $0.17. Revenue of $3.13M misses by $2.07M. Unrestricted cash, cash equivalents and investments totaled $319.7 million as of March 31, 2022, compared to $333.7 million as of December 31, 2021. For further ...